Skip to content

Ultrasound Assessment of DILAPAN-S

Longitudinal Ultrasound Evaluation of Dilapan-S During Cervical Ripening

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04529837
Enrollment
44
Registered
2020-08-28
Start date
2020-10-01
Completion date
2021-06-30
Last updated
2023-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Dilation, Induction of Labor, Ultrasound Evaluation

Brief summary

The goal of this observational prospective study is to assess the change in Dilapan-S rod diameters using transvaginal ultrasound over a period of 12 hours in term women undergoing induction of labor.

Detailed description

On admission for induction, study participants assigned to each group underwent continuous cardiotocography for 20 minutes prior to placement of the Dilapan-S rods (rod size: 4 x 65mm). Placement of the Dilapan-S rods was limited to three physicians with the majority placed by the primary investigator. Placement was completed in a sterile manner under direct visualization and in accordance with the manufacturer's guidelines. The number of rods placed varied per individual and was based on the discretion of the physician. Each participant allocated to the Dilapan-S with saturated gauze group received placement of one, 4x4 inch gauze saturated with 10 cc of normal saline and placed at the level of the external os. Immediately after placement of the Dilapan-S rods, the study participant was asked to complete a patient satisfaction survey. Pre-specified transvaginal ultrasound assessment was performed at hours 3, 6, 8, and 12 post Dilapan-S placement using a GE Voluson E10 machine with a transvaginal GE RIC 5-9D transducer. Performance of the ultrasound evaluation was limited to the primary investigator and two co-authors of the study. After completion of the 12-hour ultrasound, the Dilapan-S rods and gauze, if used, were removed as per the manufacturer's instructions. The participant was then asked to complete a post Dilapan-S patient satisfaction survey.

Interventions

OTHERGauze

placement of gauze

OTHERNo gauze

no gauze

Sponsors

Eastern Virginia Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant individuals at gestational age 37 weeks or greater. * Scheduled medical or elective induction at Sentara Norfolk General Hospital. * Live, singleton IUP. * Vertex presentation. * Intact membranes. * Bishop score of 6 or less.

Exclusion criteria

* Unwilling or unable to provide consent. * Intrauterine fetal demise * Contraindications to vaginal delivery. * BMI \> 45 * Vaginal bleeding * Clinically evident genital tract infection

Design outcomes

Primary

MeasureTime frameDescription
Diameter change of Dilapan-S12 hoursRod diameters of Dilapan-S rods were measured via transvaginal ultrasound at 3,6,8, and 12 hours after placement.

Secondary

MeasureTime frameDescription
Gauze placement and rod diameter12 hoursRod diameters of Dilapan-S rods plus gauze placement were measured via transvaginal ultrasound at 3,6,8, and 12 hours after placement.
Patient satisfaction12 hoursPatient satisfaction scores were assessed based on gauze versus no gauze placement.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026